Pancreatic cancer is the fourth most common cause of cancer-related mortality in Europe.1 Despite increased awareness, most patients continue to present with advanced disease. There has been minimal improvement in survival rates over the past 30 years, with overall 5-year survival remaining less than 8%.2 While these disappointing results are due to a multitude of host and treatment variables, it is apparent that, for a significant number of patients, poor nutritional and performance status are limiting factors to treatment choice, delivery, and tolerance.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Griffin O, Conlon KC. Sarcopenia—A New Frontier in the Management Care of Patients With Borderline Resectable Pancreatic Cancer. JAMA Surg. 2018;153(9):816. doi:10.1001/jamasurg.2018.1006
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: